Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT07647016
Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study
53 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer
RECRUITING
NCT07069712
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
100 Enrollment(s)
70 Study location(s)
INTERVENTIONAL (PHASE2)
Gastroesophageal Adenocarcinoma
RECRUITING
NCT07060807
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
1,000 Enrollment(s)
183 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Neoplasms
RECRUITING
NCT06467357
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
620 Enrollment(s)
270 Study location(s)
INTERVENTIONAL (PHASE3)
Biliary Tract Cancer
RECRUITING
NCT05950945
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
250 Enrollment(s)
88 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer
RECRUITING
NCT05573893
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
800 Enrollment(s)
107 Study location(s)
OBSERVATIONAL (None)
Breast Neoplasms


Breast Cancer


Neoplasm Metastasis
RECRUITING
NCT04047641
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
80 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Acute Myeloid Leukemia


Blasts 20 Percent or More of Bone Marrow Nucleated Cells


High Risk Myelodysplastic Syndrome


Recurrent Acute Biphenotypic Leukemia


Recurrent Acute Myeloid Leukemia


Recurrent High Risk Myelodysplastic Syndrome


Refractory Acute Myeloid Leukemia


Refractory High Risk Myelodysplastic Syndrome
NOT_YET_RECRUITING
NCT07619521
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma
31 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Advanced Pancreatic Ductal Adenocarcinoma


Metastatic Pancreatic Ductal Adenocarcinoma


Stage III Pancreatic Cancer AJCC v8


Stage IV Pancreatic Cancer AJCC v8


Unresectable Pancreatic Ductal Adenocarcinoma